1. ALLA AKTIER
  2. NYHETER
  3. VITROLIFE

Vitrolife

Nyheter Vitrolife Nyheter alla bolag

Interim report Q1, 2025: Strong performance in EMEA

REG

First quarter 

  • Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. 
  • Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. 
  • Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. 
  • Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. 
  • Gross margin increased to 57.4% (57.1). 
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. 
  • Operating cash flow amounted to SEK 69 million (198). 
  • Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).


Gothenburg, April 24, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
 

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET.

Datum 2025-04-24, kl 08:00
Källa Cision
Bifogade filer
Interim report Q1, 2025
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.